Homology Medicines (FIXX) Upgraded to “Hold” by Zacks Investment Research

Zacks Investment Research upgraded shares of Homology Medicines (NASDAQ:FIXX) from a sell rating to a hold rating in a research report sent to investors on Monday, Zacks.com reports.

According to Zacks, “Homology Medicines Inc. is a genetic medicines company. Its platform offers human hematopoietic stem cell derived adeno-associated virus vectors to treat disease-causing mutations through gene correction, insertion and knockout. Homology Medicines Inc. is based in BEDFORD MA. “

Several other analysts also recently commented on FIXX. ValuEngine downgraded shares of Homology Medicines from a buy rating to a hold rating in a report on Friday, December 7th. HC Wainwright initiated coverage on shares of Homology Medicines in a research note on Wednesday, February 20th. They issued a buy rating and a $36.00 target price for the company. Finally, Canaccord Genuity initiated coverage on shares of Homology Medicines in a research note on Monday, January 7th. They issued a buy rating and a $37.00 target price for the company. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Homology Medicines has a consensus rating of Buy and a consensus target price of $28.93.

NASDAQ:FIXX opened at $29.14 on Monday. The company has a market cap of $1.04 billion and a price-to-earnings ratio of -14.57. Homology Medicines has a twelve month low of $15.07 and a twelve month high of $31.80.

Homology Medicines (NASDAQ:FIXX) last released its earnings results on Tuesday, March 12th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.07). The company had revenue of $0.98 million for the quarter. Homology Medicines had a negative return on equity of 39.14% and a negative net margin of 1,553.07%. As a group, equities analysts expect that Homology Medicines will post -2.18 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in shares of Homology Medicines by 37.8% in the fourth quarter. Geode Capital Management LLC now owns 153,033 shares of the company’s stock valued at $3,421,000 after purchasing an additional 41,972 shares during the period. VV Manager LLC acquired a new stake in Homology Medicines in the fourth quarter valued at approximately $17,236,000. RTW Investments LP raised its holdings in Homology Medicines by 275.6% in the fourth quarter. RTW Investments LP now owns 1,633,491 shares of the company’s stock valued at $36,525,000 after acquiring an additional 1,198,574 shares in the last quarter. Legal & General Group Plc raised its holdings in Homology Medicines by 103.2% in the fourth quarter. Legal & General Group Plc now owns 3,153 shares of the company’s stock valued at $71,000 after acquiring an additional 1,601 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY acquired a new stake in Homology Medicines in the fourth quarter valued at approximately $138,000. Hedge funds and other institutional investors own 60.60% of the company’s stock.

About Homology Medicines

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Recommended Story: How to execute a trade ex-dividend strategy?

Get a free copy of the Zacks research report on Homology Medicines (FIXX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.